Xiangbin Wan

503 total citations
24 papers, 327 citations indexed

About

Xiangbin Wan is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Xiangbin Wan has authored 24 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Surgery and 8 papers in Oncology. Recurrent topics in Xiangbin Wan's work include Gastric Cancer Management and Outcomes (8 papers), Gastrointestinal Tumor Research and Treatment (7 papers) and Esophageal Cancer Research and Treatment (4 papers). Xiangbin Wan is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Gastrointestinal Tumor Research and Treatment (7 papers) and Esophageal Cancer Research and Treatment (4 papers). Xiangbin Wan collaborates with scholars based in China, United States and Norway. Xiangbin Wan's co-authors include Gangcheng Wang, Yingjun Liu, Yuzhou Zhao, Suxia Luo, Yi Li, Yong Cheng, Yaqi Zhang, Wenying Deng, Shengping Li and Yun Zheng and has published in prestigious journals such as Journal of Clinical Oncology, World Journal of Gastroenterology and Signal Transduction and Targeted Therapy.

In The Last Decade

Xiangbin Wan

23 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiangbin Wan China	10	134	122	100	84	81	24	327
Seiji Onogawa Japan	10	241 1.8×	254 2.1×	153 1.5×	127 1.5×	96 1.2×	23	475
Yunhong Tian China	10	123 0.9×	106 0.9×	77 0.8×	77 0.9×	76 0.9×	29	307
Grażyna Drabik Poland	14	134 1.0×	134 1.1×	117 1.2×	62 0.7×	100 1.2×	28	361
Tadahiko Enoki Japan	10	143 1.1×	132 1.1×	59 0.6×	110 1.3×	43 0.5×	38	332
Yasuyo Ishizaki Japan	9	204 1.5×	130 1.1×	49 0.5×	89 1.1×	64 0.8×	20	368
Jean Philippe Metges France	8	110 0.8×	224 1.8×	76 0.8×	85 1.0×	124 1.5×	23	343
Canrong Lu China	13	207 1.5×	114 0.9×	138 1.4×	50 0.6×	86 1.1×	22	368
Yueyun Chen China	9	71 0.5×	170 1.4×	57 0.6×	64 0.8×	108 1.3×	27	301
Yibo Cai China	10	76 0.6×	169 1.4×	34 0.3×	61 0.7×	55 0.7×	19	295
Xin‐Gan Qin China	11	139 1.0×	96 0.8×	69 0.7×	84 1.0×	114 1.4×	25	316

Countries citing papers authored by Xiangbin Wan

Since Specialization

Citations

This map shows the geographic impact of Xiangbin Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangbin Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangbin Wan more than expected).

Fields of papers citing papers by Xiangbin Wan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiangbin Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangbin Wan. The network helps show where Xiangbin Wan may publish in the future.

Co-authorship network of co-authors of Xiangbin Wan

This figure shows the co-authorship network connecting the top 25 collaborators of Xiangbin Wan. A scholar is included among the top collaborators of Xiangbin Wan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiangbin Wan. Xiangbin Wan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qiu, Haibo, Zhiyan Liang, Jing Yang, et al.. (2025). Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research. Signal Transduction and Targeted Therapy. 10(1). 361–361.

Li, Zhi, Wei Chen, Jian Zhang, et al.. (2025). Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial. Gastric Cancer. 28(4). 652–661. 1 indexed citations

Qiu, Haibo, Zhiwei Zhou, Ye Zhou, et al.. (2024). Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.. Journal of Clinical Oncology. 42(16_suppl). 11502–11502. 9 indexed citations

Li, Zhi, Qiang Fu, Bin Zhang, et al.. (2024). Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study. International Journal of Surgery. 110(4). 2071–2084. 13 indexed citations

Wen, Zhao, Dingchang Li, Xianqiang Liu, et al.. (2024). Nutritional and inflammatory status dynamics reflect preoperative treatment response and predict prognosis in locally advanced rectal cancer: A retrospective multi-institutional analysis. Surgery. 178. 108965–108965. 2 indexed citations

Xu, Rui‐Hua, Gong Chen, Jinfeng Ma, et al.. (2024). Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.. Journal of Clinical Oncology. 42(16_suppl). 3505–3505. 9 indexed citations

Qiu, Haibo, Zhiwei Zhou, Ye Zhou, et al.. (2023). Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology. 41(16_suppl). 11540–11540. 3 indexed citations

Zhao, Lingdi, Zhiqiang Jiang, Zhimeng Li, et al.. (2023). Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). e16074–e16074. 1 indexed citations

Li, Ning, Zhi Li, Qiang Fu, et al.. (2022). Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 40(4_suppl). 296–296. 7 indexed citations

10.

Zhou, Wenjuan, Liying Ma, Jing Yang, et al.. (2019). Potent and specific MTH1 inhibitors targeting gastric cancer. Cell Death and Disease. 10(6). 434–434. 28 indexed citations

11.

Wan, Xiangbin, Aiqin Wang, Jian Cao, et al.. (2019). Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. World Journal of Gastroenterology. 25(7). 808–823. 31 indexed citations

12.

Zhang, Ting, Feng‐Zhi Suo, Jiao Chang, et al.. (2018). Lysine‐specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC‐803. Journal of Cellular Biochemistry. 119(6). 4957–4966. 13 indexed citations

13.

Liu, Yingjun, et al.. (2017). [Surgical resection for gastric cancer patients with liver metastasis].. PubMed. 39(7). 532–535. 4 indexed citations

14.

Deng, Wenying, Nanlin Jiao, Ning Li, et al.. (2015). Decreased expression of PinX1 protein predicts poor prognosis of colorectal cancer patients receiving 5-FU adjuvant chemotherapy. Biomedicine & Pharmacotherapy. 73. 1–5. 11 indexed citations

15.

Liu, Yingjun, et al.. (2014). [Proximal gastrectomy versus total gastrectomy for adenocarcinoma of esophagogastric junction: a meta-analysis].. PubMed. 17(4). 373–7. 1 indexed citations

16.

Deng, Wenying, Ning Li, Xiangbin Wan, Suxia Luo, & Youwei Zhang. (2014). Phosphorylated insulin-like growth factor-1 receptor expression predicts poor prognosis of Chinese patients with gastric cancer. Medical Oncology. 31(12). 141–141. 4 indexed citations

17.

Liu, Yingjun, et al.. (2013). A scoring system to predict the risk of anastomotic leakage after anterior resection for rectal cancer. Journal of Surgical Oncology. 109(2). 122–125. 33 indexed citations

18.

Liu, Yingjun, Shengping Li, Xiangbin Wan, et al.. (2012). Efficacy and safety of thermal ablation in patients with liver metastases. European Journal of Gastroenterology & Hepatology. 25(4). 442–446. 40 indexed citations

19.

Zhang, Wei, Yong Shao, Chao Zhang, et al.. (2009). High-resolution melting analysis of ADAMTS18 methylation levels in gastric, colorectal and pancreatic cancers. Medical Oncology. 27(3). 998–1004. 39 indexed citations

20.

Li, Ning, et al.. (2008). Relationship between expression of CEA, E-cadherin and liver metastasis in colorectal cancer. Chinese Journal of Clinical Oncology. 5(6). 429–432. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact